Iranian Journal of Basic Medical Sciences · 6 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes preclinical studies from 2010 to 2022 on safranal, finding antioxidant, anti-inflammatory, and neuroprotective activities across multiple organ systems in animal and in-vitro models, with most evidence related to central nervous system effects. The authors conclude safranal is a promising therapeutic agent but note that more clinical studies in humans are needed to verify beneficial effects.
This narrative review searched Web of Sciences, Scopus, and Pubmed for studies on the pharmacological effects of safranal published between 2010 and June 2022. The authors report that most reviewed studies examined CNS-related effects including antianxiety, analgesic, anticonvulsant, antiischemic, anti-tremor, and memory-enhancing properties, as well as protective effects in neurodegenerative disease models. Additional reported activities include antihypertensive, antiasthmatic, anticataract, and protective effects on metabolic syndrome and diabetic nephropathy. Toxicological data indicated low acute intraperitoneal toxicity and non-toxic oral administration in rodents, with sub-acute exposure producing biochemical and hematological changes. The review is limited by its narrative design and reliance on preclinical evidence; no original human trial data are included, and the authors explicitly state that more clinical studies are needed to verify effects in humans.
